Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Inti Zlobec

Showing results (91-100 of 260) with videos related to

Pageof 26
Sort By:
Histopathology|January 28, 2010
BOB.1, CD79a and cyclin E are the most appropriate markers to discriminate classical Hodgkin's lymphoma from primary mediastinal large B-cell lymphomaSylvia Hoeller, Deborah Zihler, Inti Zlobec, et al.
Lung Cancer (Amsterdam, Netherlands)|July 21, 2009
Assessment of mean EGFR gene copy number is a highly reproducible method for evaluating FISH in histological and cytological cancer specimensInti Zlobec, Ines Raineri, Sandra Schneider, et al.
Breast (Edinburgh, Scotland)|October 22, 2011
Immunophenotyping analysis in invasive micropapillary carcinoma of the breast: role of CD24 and CD44 isoforms expressionSara Simonetti, Luigi Terracciano, Inti Zlobec, et al.
Frontiers in Medicine|September 26, 2019
Comparison of the 7th and 8th Edition of the UICC/AJCC TNM Staging System in Primary Resected Squamous Cell Carcinomas of the Lung-A Single Center Analysis of 354 CasesChristina Neppl, Manuel D Keller, Amina Scherz, et al.
Oncoimmunology|May 4, 2016
Phenotyping of tumor-associated macrophages in colorectal cancer: Impact on single cell invasion (tumor budding) and clinicopathological outcomeViktor H Koelzer, Katharina Canonica, Heather Dawson, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|September 29, 2012
Proposal for a 10-high-power-fields scoring method for the assessment of tumor budding in colorectal cancerEva Karamitopoulou, Inti Zlobec, Viktor Kölzer, et al.
Translational Research : the Journal of Laboratory and Clinical Medicine|March 24, 2015
Active immunosurveillance in the tumor microenvironment of colorectal cancer is associated with low frequency tumor budding and improved outcomeViktor H Koelzer, Heather Dawson, Emilia Andersson, et al.
International Journal of Molecular Sciences|February 13, 2026
Identification of DMP1 as Novel p53 Repressed Transcriptional TargetJun Xu, Christian Britschgi, Gustav Arvidsson, et al.
Human Pathology|March 1, 2024
The prognostic value of tumor budding in a thoroughly characterized stage II colon cancer population in the context of a national screening programMaria Pihlmann Kristensen, Ulrik Korsgaard, Signe Timm, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 15, 2024
Spatial Heterogeneity of Immune Regulators Drives Dynamic Changes in Local Immune Responses, Affecting Disease Outcomes in Pancreatic CancerEva Karamitopoulou, Anna S Wenning, Animesh Acharjee, et al.
Pageof 26

Showing results (91-100 of 260) with videos related to

Sort By:
Pageof 26
Histopathology|January 28, 2010
BOB.1, CD79a and cyclin E are the most appropriate markers to discriminate classical Hodgkin's lymphoma from primary mediastinal large B-cell lymphomaSylvia Hoeller, Deborah Zihler, Inti Zlobec, et al.
Lung Cancer (Amsterdam, Netherlands)|July 21, 2009
Assessment of mean EGFR gene copy number is a highly reproducible method for evaluating FISH in histological and cytological cancer specimensInti Zlobec, Ines Raineri, Sandra Schneider, et al.
Breast (Edinburgh, Scotland)|October 22, 2011
Immunophenotyping analysis in invasive micropapillary carcinoma of the breast: role of CD24 and CD44 isoforms expressionSara Simonetti, Luigi Terracciano, Inti Zlobec, et al.
Frontiers in Medicine|September 26, 2019
Comparison of the 7th and 8th Edition of the UICC/AJCC TNM Staging System in Primary Resected Squamous Cell Carcinomas of the Lung-A Single Center Analysis of 354 CasesChristina Neppl, Manuel D Keller, Amina Scherz, et al.
Oncoimmunology|May 4, 2016
Phenotyping of tumor-associated macrophages in colorectal cancer: Impact on single cell invasion (tumor budding) and clinicopathological outcomeViktor H Koelzer, Katharina Canonica, Heather Dawson, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|September 29, 2012
Proposal for a 10-high-power-fields scoring method for the assessment of tumor budding in colorectal cancerEva Karamitopoulou, Inti Zlobec, Viktor Kölzer, et al.
Translational Research : the Journal of Laboratory and Clinical Medicine|March 24, 2015
Active immunosurveillance in the tumor microenvironment of colorectal cancer is associated with low frequency tumor budding and improved outcomeViktor H Koelzer, Heather Dawson, Emilia Andersson, et al.
International Journal of Molecular Sciences|February 13, 2026
Identification of DMP1 as Novel p53 Repressed Transcriptional TargetJun Xu, Christian Britschgi, Gustav Arvidsson, et al.
Human Pathology|March 1, 2024
The prognostic value of tumor budding in a thoroughly characterized stage II colon cancer population in the context of a national screening programMaria Pihlmann Kristensen, Ulrik Korsgaard, Signe Timm, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 15, 2024
Spatial Heterogeneity of Immune Regulators Drives Dynamic Changes in Local Immune Responses, Affecting Disease Outcomes in Pancreatic CancerEva Karamitopoulou, Anna S Wenning, Animesh Acharjee, et al.
Pageof 26